NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT05819892 2026-03-11Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial CancerM.D. Anderson Cancer CenterPhase 1 Recruiting21 enrolled
NCT07453394 2026-03-06QLS5132 Combination Therapy in Advanced Solid TumorsQilu Pharmaceutical Co., Ltd.Phase 1/2 Not yet recruiting626 enrolled